A major barrier to all oncolytic viruses (OVs) in clinical development is cellular innate immunity, which is variably active in a spectrum of human malignancies. To overcome the heterogeneity of tumor response, we combined complementary OVs that attack cancers in distinct ways to improve therapeutic outcome. Two genetically distinct viruses, vesicular stomatitis virus (VSV) and vaccinia virus (VV), were used to eliminate the risk of recombination. The combination was tested in a variety of tumor types in vitro, in immunodeficient and immunocompetent mouse tumor models, and ex vivo, in a panel of primary human cancer samples. We found that VV synergistically enhanced VSV antitumor activity, dependent in large part on the activity of the VV B18R gene product. A recombinant version of VSV expressing the fusion-associated small-transmembrane (p14FAST) protein also further enhanced the ability of VV to spread through an infected monolayer, resulting in a "ping pong" oncolytic effect wherein each virus enhanced the ability of the other to replicate and/or spread in tumor cells. Our strategy is the first example where OVs are rationally combined to utilize attributes of different OVs to overcome the heterogeneity of malignancies and demonstrates the feasibility of combining complementary OVs to improve therapeutic outcome. 
IntroductIon
The heterogeneity and propensity of cancers to evolve resistance mechanisms is a major impediment to the development of effective anticancer therapeutics. Oncolytic viruses (OVs) that target signaling pathways and mount a multimodality attack against tumors, have the potential to revolutionize cancer therapy. [1] [2] [3] Indeed, recent clinical data demonstrate that OVs can be effective in controlling even highly evolved, standard therapy resistant, tumors. [4] [5] [6] [7] It is reasonable to expect that better outcomes could be achieved by combining OVs with current chemotherapeutics. 8 However, the ease of manipulation of viral genomes and our more complete understanding of the biology of virus-host interactions suggests that another innovative strategy would be to create OV platforms that could complement each other in tumor destruction. We reasoned that two distinct OVs, each with their own unique arsenal of weapons and attenuating mutations, could be selected to complement the other's deficits and thus in a coinfection of tumors, provide a safe, self amplifying therapeutic. To eliminate the possibility that the complementing OVs could undergo a recombination event creating a "super virus, " we used a DNA-based poxvirus and an RNA-based rhabdovirus. Vaccinia virus (VV) is a genetically complex DNA virus encoding a large number of genes, some of which have immune evading properties allowing the virus to establish local pockets of infection within an infected host. We chose a VV [double-deleted VV (VVDD)] that is restricted to tumor cell growth as it has deletions in the virally encoded thymidine kinase and VGF genes. 9 These mutations restrict the virus to productive replication in tumor cells that overexpress E2F (transcription factor that regulates cellular TK expression) and have activated epithelial growth factor receptor pathways. 10, 11 Particularly germane to this study, VVDD naturally expresses a viral gene product, B18R, that locally antagonizes the innate cellular, antiviral response initiated by type I interferons (IFNs). [12] [13] [14] [15] Our complementing virus of choice was an engineered version of the rhabdovirus VSV (vesicular stomatitis virus), an RNA-based virus exquisitely sensitive to the antiviral effects of type I IFNs. [16] [17] [18] The virtues of the VSV platform are that it is genetically simple (only five gene products) allowing it to very rapidly replicate and spread within tumors, it is strongly inhibited by IFN (a clinically approved product), can be engineered to express transgenes and is immunologically distinct from VV. We present evidence here that these two virus platforms have synergistic oncolytic activity against a range of distinct tumor types both in vitro and in vivo.
results

VV enhances VsV infection in vitro
The wild-type strain of VSV expresses a protein (the M or matrix protein) that upon infection acts as an intracellular antagonist of 
Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing
IFN production by blocking the transport of IFN mRNAs from the nucleus. 17 In earlier studies, we reported that a variant of the virus (VSVΔ51) with an engineered mutation in the M protein is unable to block the expression of IFN genes following virus infection and thus has restricted growth in normal cells that have an intact antiviral response.
17 VSVΔ51 grows to levels comparable to wild-type virus in a broad spectrum of cancer cells that lack either the ability to produce or respond to IFN. 17 However, some human tumor cell lines HT29 (colon), SKOV-3 (ovary), and 786-O ( kidney) retain at least partial responsiveness to IFN and only poorly support the spread of VSVΔ51 (Figure 1a-c) . We confirmed, however, that these VSVΔ51 resistant cell lines can be productively infected by an oncolytic version of vaccinia ( Figure 1a ) described above and herein referred to as VVDD. 9 Following infection, VVDD expresses a gene product, B18R, that binds to and locally sequesters the antiviral cytokines IFN-α/β. 12, 14, 19 To test the idea that VVDD, through the expression of B18R, could sensitize resistant tumor cells to VSV infection, we created tagged versions of VVDD [enhanced green fluorescent protein (eGFP)] and VSVΔ51 (red fluorescent protein) that would allow us to monitor the ability of each of the viruses to spread within a coinfected culture. For instance, the HT29 cells supported VVDD infection although at low multiplicities of infection, (MOI 0.1 pfu/cell) 48 hours was insufficient time for VVDD to spread throughout the monolayer (as measured by GFP expression) or complete killing of the culture (Figure 1a,b) . If VVDD infection was followed by a 1,000 times lower dose of VSVΔ51, we observed both a rapid spread of VSV and complete killing of the HT29 cell culture (Figure 1a,b) . This was true of the SKOV-3 and 786-O tumor cell lines as well (Figure 1a ). These experiments demonstrate the ability of VVDD to initiate infection of a cancer cell line and create a local environment that sensitizes a previously resistant culture to the rapid oncolytic effects of VSV. As expected, the accelerated spread of VSVΔ51 correlated with a 1,000-fold increase in virus production compared to singly infected cultures (Figure 1c) . Isobologram analysis revealed that coinfection with the two viruses resulted in synergistic killing of the cancer cell lines (Figure 1d) . Examination under fluorescence microscope revealed that, in general, the red fluorescent protein and GFP images did not overlap, suggesting that increased oncolysis was not due to enhanced uptake of VSV in VV-infected cells but rather due to sensitization of neighboring cells to VSVΔ51 infection (Figure 1a) . the VV B18R gene product enhances VsV replication in Ht29 cancer cell lines in vitro Our hypothesis was that local production of B18R (or other factors) following infection of tumor cells with VVDD creates a microenvironment depleted of bioactive antiviral cytokines thus permitting robust replication and spread of VSVΔ51. To test this idea, we first determined the IFN responsiveness of HT29 colon cancer cells by pretreating cultures with IFN-α for 17 hours followed by VSVΔ51. HT29 cells were protected from infection by VSVΔ51 but retained some susceptibility to vaccinia infection at the concentration of IFN used (Supplementary Figure S1 ). Next, we tested whether a factor secreted by VVDD infected cells was responsible for the sensitization of HT29 cells to VSVΔ51 infection. Supernatants from VVDD infected cultures were collected 24 hours after infection, filtered (to remove VVDD) and applied to naive cultures of HT29 cells. These cultures were subsequently infected with VSVΔ51 and as shown in Figure 2a , a factor(s) present in the supernatants of VVDD infected cultures was sufficient to sensitize HT29 cells to infection by VSV. To determine whether the B18R protein was at least partially responsible for the enhancement of VSVΔ51, we developed a recombinant VV strain lacking the B18R gene (VVΔB18R-eGFP). HT29 cells were infected with either VVDD or VVΔB18R alone or in combination with VSVΔ51. 100 times more VSVΔ51 produced in VVDD coinfected cultures than in VVΔB18R coinfections. As expected, filtered supernatants from VVΔB18R infected cultures were much less potent than supernatants from VVDD infected cultures at promoting VSVΔ51 spread and virus production in HT29 cells (Figure 2a,b) . Finally, purified recombinant B18R protein when added to HT29 cultures directly was able to support, in a dose dependent fashion, robust growth and spread of VSVΔ51 (Figure 2e ,g) as well as complement the VVΔB18R virus in enhancing VSVΔ51 infection of HT29 cells (Figure 2f ). The activity of B18R protein (Supplementary Figure S1 ) could be overcome by supplementing cultures with exo genous IFN-α. This is an important observation as it demonstrates that the spread of VSVΔ51 is restricted by the relative ratios of B18R and IFN-α arguing that in vivo, the growth of VSVΔ51 will be limited by the relative concentration of B18R in the tumor microenvironment.
VV enhances VsVΔ51 replication specifically in tumor beds
Nude mice bearing human HT29 subcutaneous tumors were injected intravenously with VVDD-eGFP, and the duration and biodistribution of viral infection was monitored by noninvasive optical imaging (in vivo imaging system) (Supplementary Figure S2) . As expected, 3 days after infusion, VVDD gene expression was restricted to sites of human tumor growth. 9, 20, 21 At this time, VSVΔ51-luciferase was administered intravenously and the expression of the virally encoded reporter monitored over time (Supplementary Figure S2) . We observed VSVΔ51-associated luciferase expression in tumors only in doubly infected animals. The VSVΔ51-luciferase signal peaked at ~7 days after infection but remained detectable by in vivo imaging system in the tumor for up to 11 days after infection. Importantly, during our daily monitoring of infected animals, we never observed "off-target" infections of normal tissues. We compared and contrasted VVDD and VVΔB18R viruses for their ability to promote VSV replication in tumor bearing mice (Figure 3a,b) . Although both viruses could enhance VSVΔ51 replication specifically in tumors, their relative potency in this respect mirrored our in vitro studies described above. Indeed when VVΔB18R/VSVΔ51 coinfected tumors were harvested, homogenized and analyzed for virus titers by plaque assay, we found 1,000 times more VSVΔ51 in VVDD infected tumors than in VVΔB18R infected tumors (Figure 3b) . The presence and disposition of VSV in human tumors were determined by immunohistochemical staining with anti-VSV antibodies. Although tumors infected only with VSV had little or no detectable viral proteins, as expected, there was evidence of widespread VSV infection in coinfected tumors (Figure 3c) . As we have demonstrated previously, 22 infection of tumors with VSV leads to widespread induction of apoptosis as revealed by immunohistochemical detection of active caspase 3 (Figure 3c) . We expected that with the enhanced replication of VSV in dually infected tumors, we should observe improved therapeutic outcomes. Indeed, this was the case in both human xenograft and immune competent mouse breast tumor models (Figure 3d-f) . At the treatment doses used in these experiments, we found that therapy with either virus on its own had little impact on these rapidly growing tumors and did not significantly impact cumulative survival. However when VVDD and VSV were sequentially administered, we were able to significantly slow tumor growth. In addition, the combination treatment could significantly extend survival as compared to all other treatment arms, a considerable improvement given the aggressiveness of the 4T1 breast tumor model. Most importantly in these mouse experiments, we found that virus replication even in coinfected animals was restricted to tumor beds with no evidence of infection of normal tissues detected by imaging (Figure 3a and Supplementary Figure S2) , immunohistochemical staining (Figure 3c) , and in a safety study (Supplementary Figure S3) .
VV enhances VsV expression in human tumor tissues ex vivo
The experiments described above demonstrate synergistic interactions between vaccinia and VSV oncolytics in established tumor cell lines and animal models; however, we sought to test how frequently this would be observed in intact primary human biopsy samples. Human tissue explants with specific pathologies (Supplementary Table S1), including both tumor and normal tissue (when available), were obtained from patients undergoing surgical resection. Tissue slices were prepared from each sample and then infected singly or in combination with OVs as described in Figure 4 . Viral infection was visualized by fluorescence microscopy after 48 hours. In all experiments, uninfected slices were visualized by epifluorescence microscopy to determine the level of background fluorescence emanating from the tissue. Figure 4a shows representative images of enhanced VSV infection in primary tumor samples in the presence of VVDD. For example, in one patient we were able to obtain both rectal tumor tissue and adjacent normal tissue and consistent with our mouse models, we observed OV growth only in tumor slices and not in adjacent normal tissue. Similar results were seen in a paired normal and tumor sample from a patient with metastatic colon cancer in the liver (Figure 4a) . The fluorescent images provide a qualitative readout; but to confirm that we were seeing productive infections in these samples, we quantified the amount of virus produced from the infected cultures. For these studies, immediately following the adsorption of virus, separate samples were taken to provide a baseline for the remaining input virus. At 48 hours after infection, slices were homogenized and virus titers determined. The results presented in Figure 4b are the fold enhancement of VSVΔ51 in doubly versus singly infected cultures in a wide range of malignancies. In 33 of 44 tumor samples, we observed a 10-10,000-fold increase in VSV titers following coinfection of tumor samples 
Colon#6 . Samples were processed for titration 48 hours after inoculation. Data were classified from the highest increase to the lowest one for VVDD/VSV combination. *** Not available data. A paired t-test stastistic comparing VVDD/VSV to VVDB18R/VSV. Samples tested for both VVDD/VSV and VVΔB18R/VSV were included for the statistic test. P < 0.05. with VV (Figure 4b) . In available adjacent normal samples we observed no significant infection with VSVΔ51 in the absence or presence of VVDD.
VsVΔ51 can be engineered to enhance VVdd growth
Clearly, VVDD can enhance VSVΔ51 growth by conditioning the tumor microenvironment to be nonresponsive to antiviral cytokines like IFN. We sought to create a VSVΔ51 strain that could reciprocate and produce a virally encoded gene product that would enhance VVDD growth and/or spread. Approximately 90% of VVDD produced during an infection remains inside the infected cell throughout the virus growth cycle, 23, 24 and we reasoned that if we could enhance the dissemination of VVDD from the initial infected cell, the overall virus production would be increased. To this end, we created a VSVΔ51 recombinant that expresses a fusion-associated small-transmembrane (p14 FAST) protein that locally induces cell fusion. 25, 26 The p14 FAST protein is a small integral membrane protein originally isolated from a reptilian reovirus that spontaneously initiates cell membrane fusion. We challenged the 786-O kidney cancer cell line using concentrations of viruses insufficient to elicit complete killing by either VSV or VVDD (Figure 5a,d) . In in vitro and ex vivo coinfection experiments, we found that VVDD and VSVFAST interacted in a synergistic fashion with increased cell killing (Figure 5c and Supplementary Figure S4) , virus spread of both viruses translating in over 100-fold increase in VV production (Figure 5b) .
dIscussIon
Replicating OVs have been designed or selected to specifically infect cancers and unlike tailored small molecule inhibitors, OVs attack tumors in multiple ways including direct tumor lysis, modulating tumor perfusion, and stimulation of tumor-directed innate and adaptive immune responses. 2, 3, 22, 27 We hypothesized that it should be possible to combine two distinct but complementary OV platforms to achieve better anticancer activity particularly in poorly permissive cancer types. We chose oncolytic candidates from the orthopox and rhabdovirus families for several reasons. VVDD used here grows preferentially in cancer cells that have activated epithelial growth factor receptor/ras pathways and overexpress the transcription factor E2F. The virtues of the VV platform include its highly selective growth in malignancies, its ability to be delivered intravenously, extensive safety profile in humans, large capacity to encode transgenes, and its unique complement of viral genes that modulate the environment around the primary site of infection facilitating local virus spread. VSV, on the other hand, is an RNA-based virus that has a very simple genome and has evolved a strategy of extremely rapid replication and spread to avoid innate antiviral immune responses. Indeed, one striking observation in these studies was the ability of VSV to "catch up" and surpass vaccinia spread in tumor cultures even when added at a 1,000 times lower initial inoculum.
Safety concerns have been paramount in the development of OV therapeutics and a great deal of effort has been put into the selection of viruses that have low toxicity. Unfortunately many of these attenuated platforms, while safe, have shown only limited efficacy in early human trials. 28, 29 Indeed, there have been several recent studies to engineer or select more potent viruses by including virulence genes into attenuated strains with the hope of making more clinically efficacious strains. 6, 30 A concern with this approach is the perceived, if not real, possibility of creating an "andromeda strain" virus that on its own can overcome the antiviral programs normal cells have in place to control virus spread. As an alternative to the creation of a single more virulent virus and the associated safety concerns that would go with it, we have used a genetic complementation strategy. We propose using two distinct and safe attenuated viruses that would complement each other's tumor killing abilities but were unable to grow on their own or in combination in normal cells. An important observation from this study is that, at least in the animal models tested here, the enhancement of virus growth was restricted to the tumor bed (Figure 3a and Supplementary Figure S2a) . We believe the reason for this is twofold. First, both strains are highly restricted for growth only in tumor cells. Second, the effects of the B18R protein are concentration dependent and thus only impact the immediate environment around the infected cell. Our studies with IFN demonstrate the concentration dependence of B18R for antagonizing this cytokine (Supplementary Figure  S1b) . Another critical feature of the approach described here is that opportunities for our two viruses to undergo direct recombination are eliminated as they use distinct genetic backbones (RNA versus DNA).
One of the virtues of the OV platform is the ease with which viruses can be engineered and it seems likely that additional therapeutic value can be created by engineering complementing viruses that express gene products capable of further enhancing virus spread and/or efficacy. As, but one example, we engineered a fusion protein into VSV that we reasoned could enhance VV spread. We showed that indeed a "ping pong" effect was created wherein vaccinia augmented VSV growth by expression of B18R and in return VSV expression of the fusion protein enhanced vaccinia growth (Supplementary Figure S4) . Given OV therapy is known to be associated with initiation of an adaptive immune response, one can imagine creating viruses expressing immune stimulating cytokines that may be most active when expressed sequentially. In this vein, another virtue of complementing virus platforms that we have yet to explore would be ability to effect a "prime boost" phenomena wherein the patient's immune response becomes focused on tumor antigens as two immunologically distinct virus platforms are used to effect tumor lysis. As it seems important to give multiple virus doses to achieve maximal therapeutic benefit, treatment with complementing immunologically distinct viruses may circumvent or mitigate antiviral immune responses and allow prolonged therapeutic delivery of OVs.
Isobologram analysis. 786-O cells were plated at 50,000 cells per well in 96-wells plate. Next day serial dilutions of VVDD and VSVΔ51 were added keeping a constant ratio of 100:1. Alamar blue reagent was used to assess cellular metabolic activity after 72-hour incubation. Calcusyn was used to compute the combination index, where combination index < 0.7 is considered synergistic. 32 Combination index error bars represent the standard deviation estimate.
Mice and tumor models. Mice were from Charles River Laboratories (Wilmington, MA).
Imaging studies: HT29 (3 × 10 6 ) tumors were established subcutaneously in 6-week-old CD1 female nude mice (N = 4). Palpable tumors formed within ~10 days after seeding. VVDD-eGFP was administered intravenously (1 × 10 6 pfu/mouse). VSV-Luc (1 × 10 7 pfu) was administered intravenously 2-3 days after VV treatment.
Efficacy studies: HT29 xenograft model mice were treated and tumors measured every 3-4 days using an electronic caliper. Tumor volume was calculated as (L 1 ) 2 × L 2 /2. 4T1 (1 × 10 5 cells) model (N = 10) and repeated in two other independent experiments (3 × 10 5 cells, N = 7), balb-c mice were treated with VVdd (1 × 10 7 pfu) and 2 days later with VSV (1 × 10 8 pfu). Tumors were measured as previously described. All experiments were performed in accordance with institutional guidelines review board for animal care (University of Ottawa).
In vivo imaging. Mice were injected with d-luciferin (Molecular Imaging Products, Ann Arbor, MI) for firefly luciferase imaging. Mice were anesthetized under 3% isoflurane (Baxter, Deerfield, IL) and imaged with IVIS200 Series Imaging System (Xenogen, Hopkinton, MA). Data acquisition and analysis were performed using Living Image v2.5 software. For each experiment, images were captured under identical exposure, aperture and pixel binning settings, and bioluminescence is plotted on identical color scales.
Immunohistochemistry. Tissues were harvested, placed in OCT mounting media (Tissue-Tek, Sakura Finetek, Torrance, CA). Sectioned tissues were processed as previously described with anti-VSV (1:5,000; 30 minutes) or Anti-Active Caspase 3 (1:200, 60 minutes) (25) . Tumor images were obtained with an Epson Perfection 2450 Photo Scanner (Epson, Toronto, Canada) whereas magnifications were captured using a Zeiss Axiocam HRM Inverted fluorescent microscope (Zeiss, Toronto, Canada) and analyzed using Axiovision 4.0 software. Explant tissues. Primary cancer and normal tissues specimens were obtained from consenting patients who underwent tumor resection. Samples were manually divided using a 15 mm scalpel blade into ~10-mm 3 pieces and placed on 12 wells plate with alpha medium containing 10% fetal bovine serum under sterile techniques. VVΔB18R or VVDD were added at 10 7 pfu and allowed to infect for 2 hours at 37 °C. In the last 45 minutes, VSVΔ51DsRed (10 8 pfu) was added before covering specimens with medium. At 48 hours, specimens were visualized using fluorescence microscopy. Samples were then weighted, homogenized using a homogenizer (Kinematica AG-PCU-11). Viral titers were quantified by standard plaque assay. Institutional review board of Ottawa Hospital Research Institute has approved all human studies. Declaration of Helsinki protocols were followed and patients gave their written, informed consent. Figure S1 . IFN-α experimentation. Figure S2 . Vaccinia virus enhances vesicular stomatitis virus expression into human in vivo tumor. Figure S3 . Combination vaccinia virus/rhabdovirus is safe in immunocompetent mice. Figure S4 . VVDD-VSVΔ51FAST combination enhances dramatic cancer cell issue. Table S1 . Ex vivo table with patient information.
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